Valuation: Relay Therapeutics, Inc.

Market Cap 3.57B 3.17B 2.94B 2.67B 5.05B 339B 5.13B 35.33B 13.85B 177B 13.39B 13.1B 563B P/E 2026 *
-10.1x
P/E 2027 * -10.1x
Enterprise Value 3B 2.66B 2.47B 2.25B 4.24B 284B 4.31B 29.68B 11.64B 148B 11.25B 11.01B 473B EV / Sales 2026 *
269x
EV / Sales 2027 * 174x
Free-Float
91.42%
Yield 2026 *
-
Yield 2027 * -
1 day-5.90%
1 week-8.95%
Current month-9.81%
1 month-15.16%
3 months-18.23%
6 months-2.86%
Current year+92.43%
1 week 16.13
Extreme 16.13
18.32
1 month 16.13
Extreme 16.13
19.5
Current year 7.01
Extreme 7.01
21.27
1 year 5.95
Extreme 5.95
21.27
3 years 1.78
Extreme 1.775
21.27
5 years 1.78
Extreme 1.775
37.52
10 years 1.78
Extreme 1.775
64.37
Manager TitleAgeSince
Chief Executive Officer 52 28/02/2017
Director of Finance/CFO 49 31/03/2018
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 54 03/05/2015
Director/Board Member 66 30/06/2016
Director/Board Member 52 28/02/2017
Date Insider Type Main position Quantity % Market Cap. Importance
07/10/26 Sell

Chief Executive Officer

-48,199 0.0220%
06/10/26 Sell

Chief Financial Officer

-17,717 0.0081%
08/09/26 Sell

Chief Financial Officer

-17,717 0.0081%
Change 5-day change 1-year change 3-year change Capi.($)
-5.90%-8.95%+150.85%+117.94% 3.57B
-6.60%-8.56%+49.38%+63.51% 65B
+0.03%+5.56%+9.10%+69.05% 51.2B
-4.09%-0.11%+2.22%+53.15% 51.19B
-1.53%+2.70%+30.48%+34.12% 43.93B
-1.34%+4.12%+16.64%+115.13% 41.96B
-5.97%-6.22%+228.95%+454.22% 38.14B
+6.53%+8.02%+16.40%+53.41% 33.24B
-0.90%-10.49%+37.09%-3.70% 25.2B
-1.07%+2.33%+19.43%+9.98% 22.5B
Average -2.08%-1.21%+56.05%+96.68% 37.59B
Weighted average by Cap. -2.23%-0.58%+45.26%+96.74%

Financials

2026 *2027 *
Net sales 11.16M 9.92M 9.19M 8.37M 15.79M 1.06B 16.04M 111M 43.33M 553M 41.88M 40.99M 1.76B 17.91M 15.92M 14.76M 13.43M 25.34M 1.7B 25.74M 177M 69.55M 887M 67.23M 65.8M 2.83B
Net income -320M -285M -264M -240M -453M -30.38B -460M -3.17B -1.24B -15.85B -1.2B -1.18B -50.54B -347M -309M -286M -260M -491M -32.96B -499M -3.44B -1.35B -17.2B -1.3B -1.28B -54.84B
Net Debt -571M -507M -470M -428M -807M -54.16B -820M -5.65B -2.22B -28.26B -2.14B -2.1B -90.1B -442M -393M -364M -331M -625M -41.95B -635M -4.38B -1.72B -21.89B -1.66B -1.62B -69.78B
Projected Income Statement - Annual - Relay Therapeutics, Inc.
Logo Relay Therapeutics, Inc.
Relay Therapeutics, Inc. is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. The Company's Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company's lead clinical asset, zovegalisib (RLY-2608), is the pan-mutant selective PI3Ka inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Ka-driven vascular anomalies. Its pipeline also includes programs for NRAS-driven solid tumors and Fabry disease.
Employees
202
Date Price Change Volume
16/10/26 US$16.28 -5.90% 2,366,730
15/10/26 US$17.30 +1.41% 2,117,118
14/10/26 US$17.06 -1.73% 2,936,798
13/10/26 US$17.36 -3.45% 1,706,422
12/10/26 US$17.98 +0.56% 2,090,990
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Relay Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
16.28USD
Average target price
27.58USD
Spread / Average Target
+69.43%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Relay Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. RLAY Stock